Avanos Medical, Inc.

Avanos Medical, Inc.

AVNSยทNYSE

$25.00

+0.020%
HealthcareMedical - Devices

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

At a Glance

Live Snapshot
Market Cap$1.17B
EPS-1.4600
P/E Ratio-17.12
Earnings Date08/04/2026
3Y-18.0%
5Y-3088.0%
10Y-60.0%
3Y-55.0%
5Y+150.0%
10Y-70.0%
3Y-165.0%
5Y-47.0%
10Y+2543.0%
AVNS

Avanos Medical, Inc. Cash Conversion Engine

AVNS ยท NYSE
Net Income-72.90M
Depreciation & Amortization38.90M
Stock-Based Compensation0.00
Change in Working Capital9.80M
Others98.90M
Capital Expenditures-31.60M
Free Cash Flow43.10M

Cash Flow Quality Analysis

FCF Conversion Rate

-59.1%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

42.3%

Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.

FCF Growth Trend

-48.0%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$9.80M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Cash Flow Quality Insight

Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.

Avanos Medical, Inc. Cash Flow Statement

AVNS โ€ข NYSE

Avanos Medical, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011
OPERATING ACTIVITIES
-72.9M
-392.1M
-61.8M
50.5M
5.2M
-27.2M
-45.9M
57.5M
79.3M
39.8M
-426.3M
27.1M
154.6M
152.6M
142.4M
38.9M
45.5M
46.1M
47.7M
38.3M
42.9M
36.9M
33.5M
59.5M
65.2M
65.4M
85.4M
69.2M
57.6M
51.1M
0.0
0.0
0.0
0.0
-3.4M
25.9M
-6.5M
3.7M
-6.2M
-11.5M
8.2M
-35M
-900K
-11.6M
3.5M
0.0
13.8M
15.8M
15.9M
13.2M
12.1M
10.5M
10.5M
12.6M
14.8M
14.1M
7.9M
6M
5.3M
2.6M
98.9M
398.5M
50.3M
1.1M
8M
11.6M
-9.9M
-107.4M
3.3M
-11.1M
453.2M
49.7M
6.8M
-10.9M
8.3M
(14.1M)
(3.3M)
(23.6M)
(0.0)
(0.0)
(0.0)
(8.4M)
(96.6M)
(21.4M)
(29.1M)
-43.3M
(87.6M)
(74.2M)
(94.3M)
(0.0)
9.8M
35M
-18M
-24.3M
26M
-67.8M
-59.6M
-143.4M
-4.3M
91.6M
-17M
12.8M
-11.9M
9.6M
-68.3M
74.7M
100.7M
32.4M
90.9M
87.3M
-2.5M
-74.5M
-145.6M
144.2M
188.8M
97.6M
147.9M
223.8M
202.6M
139.6M
INVESTING ACTIVITIES
-31.6M
-17.8M
-17.8M
-19.3M
-21M
-20.2M
-50.6M
-49.1M
-43.2M
-29.1M
-70.4M
-78.5M
-49M
-40.8M
-39.7M
-28M
-9.7M
(39.4M)
-116.1M
(0.0)
-4M
-57.5M
(688.6M)
(100K)
-175M
(7.8M)
(0.0)
-2.2M
(0.0)
-3.7M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-2.2M
(0.0)
(0.0)
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
49M
0.0
0.0
-1M
0.0
0.0
0.0
0.0
0.0
0.0
754.3M
100K
3.2M
7.8M
7.8M
-46.5M
500K
3.9M
-60.6M
-27.5M
(21.6M)
-135.4M
-21M
-24.2M
-108.1M
(639.5M)
-43.1M
-200.9M
-62.6M
-70.7M
-50.9M
-40.3M
-39.5M
FINANCING ACTIVITIES
-2.6M
-12.8M
-19.1M
-45.5M
-11.5M
-900K
-3.6M
-900K
-2.5M
-900K
-1M
0.0
0.0
0.0
0.0
-34.4M
-33.6M
-64.7M
103.4M
-50M
-69.8M
-200K
-339M
0.0
-900K
-51M
624.2M
-63.9M
-24.1M
11.8M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-680M
(0.0)
(0.0)
(0.0)
-3.3M
-12.8M
-19.1M
-45.5M
-11.5M
-900K
-3.6M
-900K
-2.5M
-900K
-1M
(0.0)
(0.0)
(0.0)
(0.0)
0.0
-2.7M
-10.4M
-1.2M
6.2M
700K
5.3M
15.5M
4.7M
400K
1.4M
-595M
-116.1M
-109.8M
-126.9M
-37M
-49.1M
-94.2M
56.7M
-55.3M
-70M
1.5M
-324.4M
2.2M
-1.4M
-50.6M
29.2M
-180M
-133.9M
-115.1M
CASH FLOW SUMMARY
5M
-4.1M
200K
-3M
-4M
2.9M
1.9M
-4.7M
2.7M
-2.3M
-3.9M
-1.5M
3.3M
-600K
800K
-17.9M
20M
-40M
9.2M
7M
-93.8M
-179.2M
164.8M
106M
-15.8M
-19.5M
104.9M
-3.8M
27.8M
-14.2M
107.7M
87.7M
127.7M
118.5M
111.5M
205.3M
384.5M
219.7M
113.7M
129.5M
149M
44.1M
47.9M
20.1M
34.3M
89.8M
107.7M
87.7M
127.7M
118.5M
111.5M
205.3M
384.5M
219.7M
113.7M
129.5M
149M
44.1M
47.9M
20.1M
43.1M
82.9M
14.6M
71.6M
66.3M
-22.7M
-125.1M
-194.7M
101M
159.7M
27.2M
69.4M
174.8M
161.8M
99.9M

SEC Filings

AVNS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 05, 2026
May 05, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 05, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 14, 2026
April 13, 2026
2026
8-K

8-K 2026

N/A

March 12, 2026
March 06, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 12, 2026
April 21, 2026
2026
8-K

8-K 2026

N/A

February 26, 2026
February 25, 2026
2026
10-K

10-K 2025 FY

FY

February 24, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 24, 2026
February 24, 2026
2026
8-K

8-K 2026

N/A

January 13, 2026
January 13, 2026
2026
8-K/A

8-K/A 2025 (Amended)

N/A

December 05, 2025
October 21, 2025
2025
Showing 1 to 10 of 178 filings